Hsp90 inhibitors in the clinic

Handbook of Experimental Pharmacology

Volumn 172, Issue , 2006, Pages 331-358

  Pacey, S ^a   Banerj, U ^b   Judson, I ^a   Workman, P ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Clinical; Disease; Hsp90; Inhibitor; Trial

Indexed keywords

EID: 85099486499     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-29717-0_14     Document Type: Article

References (128)

1. AnWG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11:355-360
2. Armstrong BK, Kricker A (1994) Cutaneous melanoma. Cancer Surv. 19-20:219-240
3. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinsons disease. Science 295:865-868
4. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3:1021-1030
5. Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33 Suppl:238-244
6. BanerjiU,WaltonM, Raynaud F,KellandLR, Judson I,WorkmanP (2001)Validation of pharmacodynamic endpoints for the Hsp90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17-AAG) in a human tumour xenograft model. Proc Am Asso Cancer Res 42:833
7. Banerji U, ODonnell A, Scurr M, Benson C, Stapleton S, Raynaud F, Clarke PA, Turner A, Workman P, Judson I (2003) A pharmacokinetically (PK) - pharmacodynamically (PD) guided phase I trial of the heat shock protein (Hsp90) inhibitor 17-Allylamino, 17- demethoxygeldanamycin (17AAG). Proc Am Soc Clin Oncol 22:199
8. Banerji U, ODonnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I (2005) A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in patients with advanced malignancies. J Clin Oncol 23:4152-4161)
9. BanerjiU,WaltonM,Raynaud F,GrimshawR,KellandLR,Valentini M, Judson I,WorkmanP (2005b) Pharmacokinetic-Pharmacodynamic relationships for the HSP90 molecular chaperone inhbitors 17-Allylamino, 17-demethoxygeldanamycin (17-AAG) in human ovarian cancer models. Clin Cancer Res (in press)
10. Barral JM, Broadley SA, Schaffar G, Hartl FU (2004) Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 15:17-29
11. Baselga J, Albanell J,Molina MA, Arribas J (2001)Mechanism of action of trastuzumab and scientific update. Semin Oncol 28:4-11
12. Bearss DJ, Hurley LH, Von Hoff DD (2000) Telomere maintenance mechanisms as a target for drug development. Oncogene 19:6632-6641
13. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L (2003) Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 9:4961-4971
14. Braga-BasariaM,Hardy E,GottfriedR,BurmanKD, SajiM,RingelMD(2004) 17-Allylamino- 17-demethoxygeldanamycin activity against thyroid cancer cell lines correlateswith heat shock protein 90 levels. J Clin Endocrinol Metab 89:2982-2988
15. Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377-387
16. Chabner BA, Roberts TG (2005) Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5:65-72
17. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64:5913-5919
18. Cheung KM,Matthews T, James K, AherneW, Rowlands M, Boxall K, Sharp S, Prodromou C, Pearl L, McDonald E, Workman P (2005) The identification, synthesis and in vitro biochemical evaluation of a new class of Hsp90 inhibitors. J Med Chem Bioorg Med Chem Lett 15:3338-3343
19. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883
20. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N (2002) Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 10:3555-3564
21. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L (2003) 1AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2:123-129
22. Chiosis G, Vilenchik M, Kim J, SolitD (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9:881-888
23. Choo-Kang LR, Zeitlin PL (2001) Induction ofHsp70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 281:L58-L68
24. Chung J, Yoon S, Datta K, Bachelder RE, Mercurio AM (2004) Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells. Cancer Res 64:4711-4716
25. Chung YL, Troy H, Banerji U, Jackson LE, Walton M, Stubbs M, Griffiths JR, Judson I, Leach MO, Workman P, Ronen SM (2003) Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protien inhibitor 17-allyamino, 17-demethoxygeldanamycin (17-AAG) in human colon cancer models. J Natl Cancer Inst 95:1624-1633
26. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133
27. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426:905-909
28. Daude N, Marella M, Chabry J (2003) Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 116:2775-2779
29. daRocha Dias S, Light Y, Friedlos F, Springer C,Workman P, Marais R (2005) Oncogenic BRAF is an Hsp90 client protein that is targetted by the anti-cancer drug 17-AAG. Cancer Res (in press)
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V,Menzies A,Mould C, Parker A, Stevens C,Watt S, Hooper S,Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-TrenchG,Riggins GJ,BignerDD, Palmieri G, CossuA, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R,Marshall CJ,Wooster R, StrattonMR, Futreal PA (2002)Mutations of the BRAF gene in human cancer. Nature 417:949-954
31. De Carcer G, do Carmo Avides M, Lallena MJ, Glover DM, Gonzalez C (2001) Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J 20:2878-2884
32. DeVita VT Jr, Hellman S, Rosenberg SA (2001) Cancer : principles and practise of oncology, 6 edn. Lippincott,Williams andWilkins, Philadelphia
33. Druker BJ (2003) David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 21:239S-245S
34. Dymock B, Drysdale M, McDonald E, Workman P (2004) Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin Ther Patents 14:837-847
35. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P, Wright L, Drysdale MJ (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48:4212-4215
36. Eder JP,Wheeler CA, Teicher BA, Schnipper LE (1991) A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res 51:510-513
37. EgorinMJ,Zuhowski EG,RosenDM,Sentz DL,Covey JM,Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CDF1 mice. Cancer Chemother Pharmacol 47:291-302
38. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
39. Eiseman JL, Lan J, Lagattuta TF,HamburgerDR, Joseph E, Covey JM, EgorinMJ (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl] amino]geldanamycin(1DMAG,NSC707545) in C.B-17 SCID mice bearingMDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55:21-32
40. Ellis GK, Crowley J, Livingston RB, Goodwin JW, Hutchins L, Allen A (1991) Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer 67:2969-2973
41. Erlichman C, Toft D, Reid J, Sloan J, Atherton P, Adjei A, Ames M, Croghan G (2001) A phase I trial of 17 allylamino geldanamycin in patients with advanced cancer. Proc Am Asso Cancer Res 42:833
42. Erlichman C, Toft D, Reid J, GoetzM, Ames M, Mandrekar A, Ajei A, McCollum A, Ivy P (2004) A Phase I trial of 17-allylamino-geldanamycin) (1AAG) in patients with advanced cancer (abstract). Proc Am Assoc Clin Oncol 23:3030
43. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE (2001) Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J Biol Chem 276:15571-15574
44. Fuller W, Cuthbert AW (2000) Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate. J Biol Chem 275:37462-37468
45. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P (1999) Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91:1281-1287
46. George P, Bali P, Annavarapu S, Scuto A, FiskusW, Guo F, Sigua C, Sondarva G,Moscinski L, Atadja P, Bhalla K (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT. Blood 105:1768-1776
47. Goetz M, Toft D, Reid J, Sloan J, Atherton P, Adjei A, Croghan G, WeinshilboumR, Erlichman C, Ames M (2002) A phase I trial of 17-allyaminodemethoxygeldanamycin (17- AAG) in patients with advanced cancer. Proceedings EORTC-NCI-AACR Symposium of Molecular Cancer Therapeutics. Eur J Cancer 38 [Suppl]:S54
48. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087
49. Gore L, Holden SN, BascheM, Raj SKS, Arnold I, OBryant C, Witta S, Rohde B, McCoy C, Eckhardt SG (2004) Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumours. Proc Am Soc Clin Oncol 22:3026
50. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880
51. Gossett DR, Bradley MS, Jin X, Lin J (2005) 17-Allyamino-17- demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol 96:381-388
52. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893
53. Grenert JP, SullivanWP, FaddenP,HaysteadTA, Clark J,MimnaughE, KrutzschH, OchelHJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850
54. Hanahan D,Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
55. Hollingshead M, Alley M,BurgerAM,Borgel S, Pacula-Cox C, FiebigHH,Sausville EA(2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. Cancer Chemother Pharmacol 56:115-125
56. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibtion of signal transduction by Hsp90 inhibitor 17-allylamino, 17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009
57. Itoh H, Ogura M, Komatsuda A,Wakui H, Miura AB, Tashima Y (1999) A novel chaperoneactivity- reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochem J 343:697-703
58. Jaattela M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248:30-43
59. Jemal A, Thomas A,MurrayT, ThunM(2002) Cancer statistics, 20CA. Cancer JClin 52:23-47
60. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A highaffinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
61. Kawano R, Ohshima K, Karube K, Yamaguchi T, Kohno S, Suzumiya J, Kikuchi M, Tamura K (2004) Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol 127:305-307
62. Kelland LR, Sharp SY, Rogers PM,Myers TG,Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949
63. Kiang JG, Bowman PD, Wu BW, Hampton N, Kiang AG, Zhao B, Juang YT, Atkins JL, Tsokos GC (2004) Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible Hsp70. J Appl Physiol 97:564-569
64. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates?Nat Rev Drug Discov 3:711-715
65. Kristeleit RS, Tandy D, Atadja P, Patnaik A, Scott J, De Bono JS, Judson I, Kaye SB, Workman P, Aherne W (2004) Effects of the histone deacetylase inhibitor (HDACi) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes frompatients with advanced solid tumours enrolled in a phase I clinical trial. Proc Am Soc Clin Oncol 22:3032
66. Kumar R,Musiyenko A, Barik S (2003) The heat shock protein 90 of Plasmodiumfalciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J 2:30
67. Latchman DS (2001)Heat shock proteins and cardiac protection. CardiovascRes 51:637-646
68. Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G (2005) Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 48:2892-2905
69. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609-1614
70. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302:871-874
71. Maloney A, Workman P (2002) Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3-24
72. Manola J,AtkinsM,IbrahimJ, KirkwoodJ (2000)Prognostic factors in metastaticmelanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793
73. MarcuM,Neckers L (2003) The C-Terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr Cancer Drug Targets 3:343-347
74. MarcuMG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181-37186
75. Matthews RC, Burnie JP (2004) Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22:865-871
76. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J (2003)Preclinical assessment of the efficacy ofmycograb, ahumanrecombinant antibody against fungal HspAntimicrob Agents Chemother 47:2208-2216
77. Minet E,MottetD, Michel G,Roland I, RaesM,Remacle J, MichielsC(1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460:251-256
78. Mitsiades C, Chanan-Khan A, Alsina M, Dass D, Landrigan D, Keitner M, Albitar GF, Hannah AL, Richardson P (2005) Phase I trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). Proc American Assoc Clin Onc 23:3056
79. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP,Munshi NC, Richardson PG,Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379
80. Nardai G, Sass B, Eber J, Orosz G, Csermely P (2000) Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch Biochem Biophys 384:59-67
81. Neckers L, Ivy P (2003). Heat Shock Protein 90. Curr Opin Oncol 15:419-24
82. Nooney L, Matthews RC, Burnie JP (2005) Evaluation of mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis. 51:19-29
83. Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20:42S-46S
84. Ochel HJ, Gademann G (2004) Destabilization of the non-pathogenic, cellular prion-protein by a small molecular drug. Antivir Ther 9:441-445
85. OkabeM,Uehara Y, Miyagishima T, Itaya T, TanakaM, Kuni-Eda Y, Kurosawa M, Miyazaki T (1992) Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoproteinassociated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80:1330-1338
86. Okada M, Itoh H,Hatakeyama T, Tokumitsu H,KobayashiR(2003) Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J 374:433-441
87. Orr HT (2004) Neurodegenerative disease: neuron protection agency. Nature 431:747-748
88. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
89. Prodromou C, Roe SM, OBrien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65-75
90. Ramanathan RK, Trump DL, Eiseman JL, Belani P, Agarwala S, Zuhowski EG, Lan J, Ivy P (2004) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamcyin (17-AAG, NSC-704057) in patients with advanced tumors (abstract). Proc Am Assoc Clin Oncol 23:3031
91. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
92. Rosenhagen MC, Soti C, Schmidt U, Wochnik GM, Hartl FU, Holsboer F, Young JC, Rein T (2003) The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 17:1991-2001
93. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH,Workman P, Aherne W(2004) Highthroughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327:176-183
94. Rutherford SL, Lindquist S (1998) Hsp90 as a capacitor formorphological evolution. Nature 396:336-342
95. Santos NC, Figueria-Coelho J,Martin-Silva J (2003)Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellularandmolecular aspects.BiochemPharmacol 65:1035-1041
96. Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to HspProc Natl Acad Sci U S A 97:10832-10837
97. Sausville EA, Tomaszewski JE, Ivy P (2003) Clinical development of 17-allylamino, 17- demethoxygeldanamycin. Curr Cancer Drug Targets 3:377-383
98. Scherer FM (2004) The pharmaceutical industry-prices and progress. N Engl J Med 351:927-932
99. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL,Muzzi ML, DiOrio CI, Barbacci EG,Miller PE et al. (1995) erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. JMed Chem 38:3813-3820
100. Schulte TW, BlagosklonnyMV, Romanova L,Mushinski JF,Monia BP, Johnston JF, Nguyen P, Trepel J,NeckersLM(1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839-5845
101. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002)Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125
102. Sheriff M, Clarke PA,Workman P (2004) Factors that govern the cell death response induced by inhibition of the molecular chaperone heat shock protein 90. Eur J Cancer 2:97
103. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
104. Sittler A, LurzR, Lueder G, Priller J, Lehrach H,Hayer-Hartl MK,HartlFU,Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntingtons disease. Hum Mol Genet 10:1307-1315
105. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19
106. Soga S, Shiotsu Y, Akinaga S, Sharma SV (2003) Development of radicicol analogues. Curr Cancer Drug Targets. 3:359-369
107. Soldano KL, Jivan A, Nicchitta CV, Gewirth DT (2003) Stucture of the N-terminal domain of GRP94: basis for ligand specificity and regulation. J Biol Chem 48:48330-48338
108. SolitDB, ZhengFF,DrobnjakM,MunsterPN,HigginsB,VerbelD,HellerG, TongW,Cordon- Cardo C,AgusDB, Scher HI,RosenN(2002) 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
109. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N (2003a) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-2144
110. Solit DB, Scher HI, Rosen N (2003b) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-716
111. Solit DB, Egorin M, Valetin G, Delacruz QYe, Schwartz L, Larson N, Rosen N, Scher HI (2004) A Phase 1 pharmacokinetic and pharmacodynamic trial of decetaxol and 1AAG (17-allylamin-17-demethoxygeldanamycin). Proc Am Assoc Clin Oncol 22:3032
112. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250
113. Sugita T, Tanaka S, Murakami T, Miyoshi H, Ohnuki T (1999) Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin. Biochem Mol Biol Int 47:587-595
114. Supko JG,Hickman RL, GreverMR,Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-515
115. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, EisenbergerMA(2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
116. Toms JR (2004) CancerStats Monograph. Cancer Research UK, London
117. Tsan MF, Gao B (2004) Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 286:C739-C744
118. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato dP, Sciot R, van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 [Suppl] 5:S83-S87
119. Wax S, Piecyk M,Maritim B, Anderson P (2003) Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum 48:541-550
120. WeberD(2003) Thalidomide and its derivatives: new promise formultiplemyeloma. Cancer Control 10:375-383
121. Weissmann C (2004) The state of the prion. Nat Rev Microbiol. 2:861-871
122. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH (1998) The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18:1517-1524
123. Workman P (2005) Genomics and the second golden era of cancer drug development. Molecular BioSystems in press
124. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206:149-157
125. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE (2004) Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem Biol 11:775-785
126. Xu L, Eiseman JL, Egorin MJ,DArgenio DZ (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185-219
127. XuW, Mimnaugh E, RosserMF,Nicchitta C,MarcuM, Yarden Y,Neckers L (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708
128. Yu X,Guo ZS,MarcuMG,Neckers L,NguyenDM, Chen GA, SchrumpDS (2002)Modulation of p53,ErbB1,ErbB2,andRaf-1 expressionin lungcancer cellsbydepsipeptide FR901228. J Natl Cancer Inst 94:504-513